

**BIOCON GROUP**

**FACT SHEET**

**June - 2023**

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	Q1 FY 24	Q1 FY 23	Variance %
<b><u>INCOME</u></b>			
Generics	700	607	15%
Biosimilars	2,015	977	106%
Novel Biologics	-	-	0%
Research services	808	645	25%
Inter-segment	(101)	(89)	13%
<b>Revenue from operations #</b>	<b>3,423</b>	<b>2,140</b>	<b>60%</b>
Other income	94	78	20%
<b>TOTAL REVENUE</b>	<b>3,516</b>	<b>2,217</b>	<b>59%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	1,324	795	67%
Staff costs	520	463	12%
Research & Development expenses*	315	198	59%
Other expenses	550	285	93%
<b>Manufacturing, staff &amp; other expenses</b>	<b>2,708</b>	<b>1,740</b>	<b>56%</b>
<b>EBITDA</b>	<b>808</b>	<b>478</b>	<b>69%</b>
Interest & Finance charges	233	20	1045%
Depreciation & Amortisation	358	217	65%
Share of loss / (profit) in JV / Associate, net	33	43	-23%
<b>PBT</b>	<b>184</b>	<b>197</b>	<b>-7%</b>
Exceptional item	-	-	-
<b>PBT</b>	<b>184</b>	<b>197</b>	<b>-7%</b>
Taxes	35	30	18%
Taxes on exceptional item	-	-	0%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>149</b>	<b>167</b>	<b>-11%</b>
Minority interest	48	23	107%
Minority interest on exceptional item	-	-	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>101</b>	<b>144</b>	<b>-30%</b>
<b>EPS Rs.</b>	<b>0.8</b>	<b>1.2</b>	
<b><u>NET PROFIT BEFORE EXCEPTIONAL ITEM</u></b>			
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>	<b>101</b>	<b>144</b>	<b>-30%</b>
Exceptional item, net of taxes	-	-	0%
<b>NET PROFIT FOR THE PERIOD</b>	<b>101</b>	<b>144</b>	<b>-30%</b>
<i># Licensing Income</i>	167	9	
<i>* Gross Research &amp; Development expenses</i>	324	223	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
<b>Particulars</b>	<b>Q1 FY 24</b>	<b>Q4 FY 23</b>	<b>Variance %</b>
<b><u>INCOME</u></b>			
Generics	700	752	-7%
Biosimilars	2,015	2,102	-4%
Novel Biologics	-	19	100%
Research services	808	994	-19%
Inter-segment	(101)	(93)	8%
<b>Revenue from operations #</b>	<b>3,423</b>	<b>3,774</b>	<b>-9%</b>
Other income	94	155	-40%
<b>TOTAL REVENUE</b>	<b>3,516</b>	<b>3,929</b>	<b>-11%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	1,324	1,343	-1%
Staff costs	520	529	-2%
Research & Development expenses*	315	342	-8%
Other expenses	550	563	-2%
<b>Manufacturing, staff &amp; other expenses</b>	<b>2,708</b>	<b>2,777</b>	<b>-2%</b>
<b>EBITDA</b>	<b>808</b>	<b>1,152</b>	<b>-30%</b>
Interest & Finance charges	233	248	-6%
Depreciation & Amortisation	358	364	-2%
Share of loss / (profit) in JV / Associate, net	33	40	-17%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>184</b>	<b>500</b>	<b>-63%</b>
Exceptional item, Net	-	(3)	-100%
<b>PBT</b>	<b>184</b>	<b>497</b>	<b>-63%</b>
Taxes	35	59	-41%
Taxes on exceptional item	-	23	-100%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>149</b>	<b>415</b>	<b>-64%</b>
Minority interest	48	106	-55%
Minority interest on exceptional item	-	(4)	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>101</b>	<b>313</b>	<b>-68%</b>
<b>EPS Rs.</b>	<b>0.8</b>	<b>2.6</b>	
<b><u>NET PROFIT BEFORE EXCEPTIONAL ITEM</u></b>			
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>	<b>101</b>	<b>335</b>	<b>-70%</b>
Exceptional item	-	(22)	
<b>NET PROFIT FOR THE PERIOD</b>	<b>101</b>	<b>313</b>	<b>-68%</b>
<i># Licensing Income</i>	167	175	
<i>* Gross Research &amp; Development expenses</i>	324	356	

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>BALANCE SHEET</b>		
(Rs Crores)		
<b>Particulars</b>	<b>June 30, 2023</b>	<b>March 31, 2023</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	7,174	7,277
(b) Capital work-in-progress	2,900	2,588
(c) Right-of-use assets	376	258
(d) Goodwill	16,120	16,136
(e) Other intangible assets	5,660	5,796
(f) Intangible assets under development	4,778	4,730
(g) Investment in associates and a joint venture	105	138
(h) Financial assets	-	-
Investments	560	605
Derivative assets	243	145
Other financial assets	1,089	1,083
(i) Income tax asset, net	377	354
(j) Deferred tax asset, net	286	301
(k) Other non-current assets	288	298
<b>Non-current assets</b>	<b>39,956</b>	<b>39,709</b>
<b>Current assets</b>		
(a) Inventories	4,471	4,244
(b) Financial assets		
Investments	2,087	1,327
Trade receivables	3,609	3,573
Cash and cash equivalents	922	1,324
Other bank balances	1,092	1,077
Derivative assets	117	70
Other financial assets	103	132
(c) Other current assets	868	588
(c) Assets held for sale	-	-
<b>Current assets</b>	<b>13,269</b>	<b>12,334</b>
<b>TOTAL - ASSETS</b>	<b>53,225</b>	<b>52,043</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	600	600
(b) Other equity	18,261	17,267
<b>Equity attributable to owners of the Company</b>	<b>18,861</b>	<b>17,867</b>
Non-controlling interests	5,228	4,622
<b>Total Equity</b>	<b>24,089</b>	<b>22,489</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	15,839	15,291
Lease liabilities	273	209
Derivative liabilities	-	26
Other financial liabilities	4,995	4,620
(b) Provisions	232	227
(c) Deferred tax liability, net	392	382
(d) Other non-current liabilities	309	290
<b>Non-current liabilities</b>	<b>22,040</b>	<b>21,043</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	1,298	2,480
Lease liabilities	63	39
Trade payables	3,782	3,983
Derivative liabilities	23	59
Other financial liabilities	426	467
(b) Provisions	183	149
(c) Income tax liability, net	257	225
(d) Other current liabilities	1,064	1,109
(e) Liabilities classified as held for sale	-	-
<b>Current liabilities</b>	<b>7,096</b>	<b>8,511</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>53,225</b>	<b>52,043</b>